Nuwellis Inc
NUWE2.160USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
2.95MMarket Cap
0.01P/E TTM
More Details of Nuwellis Inc Company
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Nuwellis Inc Info
Ticker SymbolNUWE
Company nameNuwellis Inc
IPO dateFeb 16, 2012
CEOErb (John L)
Number of employees38
Security typeOrdinary Share
Fiscal year-endFeb 16
Address12988 Valley View Rd
CityEDEN PRAIRIE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55344
Phone19523454200
Websitehttps://www.nuwellis.com/
Ticker SymbolNUWE
IPO dateFeb 16, 2012
CEOErb (John L)
Company Executives of Nuwellis Inc
Name
Name/Position
Position
Shareholding
Change
Erb (John L)
Erb (John L)
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
803.00
--
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
3.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
3.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Mccormick
Mr. Michael (Mike) Mccormick
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Erb (John L)
Erb (John L)
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
803.00
--
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
3.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
3.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
2.18%
Sabby Management, LLC
2.16%
Bigger Capital Funds, LP
0.34%
UBS Financial Services, Inc.
0.17%
Citi Investment Research (US)
0.13%
Other
95.02%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
2.18%
Sabby Management, LLC
2.16%
Bigger Capital Funds, LP
0.34%
UBS Financial Services, Inc.
0.17%
Citi Investment Research (US)
0.13%
Other
95.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.35%
Investment Advisor/Hedge Fund
2.16%
Hedge Fund
0.41%
Research Firm
0.13%
Individual Investor
0.02%
Other
94.93%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
18
13.52K
2.03%
+10.09K
2025Q2
27
9.97K
1.46%
+7.11K
2025Q1
26
140.31K
3.15%
+23.64K
2024Q4
25
113.78K
2.60%
+73.44K
2024Q3
29
65.32K
2.68%
+45.76K
2024Q2
28
42.02K
3.15%
+30.15K
2024Q1
26
9.25K
4.91%
+1.97K
2023Q4
26
6.22K
6.75%
+3.61K
2023Q3
35
1.28K
4.82%
-1.76K
2023Q2
36
1.31K
5.00%
-797.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
3.52K
0.67%
+3.52K
--
Jun 30, 2025
Bigger Capital Funds, LP
5.69K
0.63%
+5.69K
--
Jun 09, 2025
UBS Financial Services, Inc.
1.88K
0.36%
+1.78K
+1797.98%
Jun 30, 2025
Tower Research Capital LLC
132.00
0.01%
-14.00
-9.59%
Jun 30, 2025
Erb (John L)
803.00
0.02%
+803.00
--
Jun 10, 2025
SBI Securities Co., Ltd.
61.00
0.01%
+52.00
+577.78%
Jun 30, 2025
The Vanguard Group, Inc.
31.00
0%
--
--
Aug 31, 2025
BofA Global Research (US)
1.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 02, 2025
Merger
42→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Dec 09, 2022
Merger
100→1
Date
Type
Ratio
Jul 02, 2025
Merger
42→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Dec 09, 2022
Merger
100→1
Dec 09, 2022
Merger
100→1
Dec 09, 2022
Merger
100→1
Dec 09, 2022
Merger
100→1
Oct 17, 2020
Merger
30→1
View more
FAQs
Who are the top five shareholders of Nuwellis Inc?
The top five shareholders of Nuwellis Inc are:
Sabby Management, LLC holds 3.52K shares, accounting for 0.67% of the total shares.
Bigger Capital Funds, LP holds 5.69K shares, accounting for 0.63% of the total shares.
UBS Financial Services, Inc. holds 1.88K shares, accounting for 0.36% of the total shares.
Tower Research Capital LLC holds 132.00 shares, accounting for 0.01% of the total shares.
Erb (John L) holds 803.00 shares, accounting for 0.02% of the total shares.
Sabby Management, LLC holds 3.52K shares, accounting for 0.67% of the total shares.
Bigger Capital Funds, LP holds 5.69K shares, accounting for 0.63% of the total shares.
UBS Financial Services, Inc. holds 1.88K shares, accounting for 0.36% of the total shares.
Tower Research Capital LLC holds 132.00 shares, accounting for 0.01% of the total shares.
Erb (John L) holds 803.00 shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of Nuwellis Inc?
The top three shareholder types of Nuwellis Inc are:
DRW Securities, LLC
Sabby Management, LLC
Bigger Capital Funds, LP
DRW Securities, LLC
Sabby Management, LLC
Bigger Capital Funds, LP
How many institutions hold shares of Nuwellis Inc (NUWE)?
As of 2025Q3, 18 institutions hold shares of Nuwellis Inc, with a combined market value of approximately 13.52K, accounting for 2.03% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.57%.
What is the biggest source of revenue for Nuwellis Inc?
In --, the -- business generated the highest revenue for Nuwellis Inc, amounting to -- and accounting for --% of total revenue.
